Drug Profile
Clindamycin/tretinoin
Latest Information Update: 24 Jun 2015
Price :
$50
*
At a glance
- Originator Skinvisible Pharmaceuticals
- Developer Embil Pharmaceutical; Skinvisible Pharmaceuticals
- Class Antiacnes; Antibacterials; Keratolytics; Lincosamides; Retinoids; Small molecules
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Acne
Most Recent Events
- 24 Jun 2015 No recent reports on development identified - Preregistration for Acne in Indonesia, Philippines, Malaysia, Azerbaijan, Kyrgyzstan, Turkmenistan, Uzbekistan, Turkey and Kazakhstan (Topical)
- 16 May 2008 Clindamycin/tretinoin is available for licensing worldwide (http://www.skinvisible.com)
- 13 May 2008 Clinical trials in Acne in USA (Topical)